Sand 9, Inc., a pioneer in precision MEMS timing products for wireless and wired applications, announced that Ericsson (NASDAQ: ERIC), a worldleading provider of telecommunications equipment and services to mobile and fixed network operators, has invested $3 million in the company. Sand 9’s micro-electromechanical systems (MEMS) timing products offer significant advantages over legacy quartz crystal solutions, which currently dominate this market. Sand 9’s timing products offer greater immunity to electromagnetic interference (EMI) and vibration in combination with low noise and high stability, which ensures precision timing – even in ruggedized environments. Founded in 2007 in Cambridge, MA, Sand 9 is a pioneer in advanced MEMS timing technology.
http://www.sand9.com
Solarmer Energy, Inc., and Phillips 66 (NYSE: PSX) South China University of Technology (SCUT), and have successfully set a new world record in power conversion efficiency for polymer-based organic photovoltaic (OPV) cells. The 9.31 percent efficiency was certified by the Newport Technology & Application Center’s Photovoltaic Lab in Long Beach, Calif. Solarmer is developing transparent, lightweight, flexible, plastic solar panels, which are expected to cost a fraction of what silicon solar panels cost. These solar panels will create new markets that are currently not addressable with conventional silicon solar panel technology. The company was founded in 2006 to commercialize technology developed at UCLA. It now is based in El Monte, Calif., USA.
http://www.solarmer.com http://www.phillips66.com
Starpharma Holdings Ltd (OTCQX: SPHRY) announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology. Under the agreement Astra-Zeneca will undertake oncology studies using specific Starpharma Holdings also announced completion of recruitment in its two Phase 3 trials investigating Vi- vaGel® as a treatment for bacterial vaginosis (BV). The Phase 3 treatment trials were conducted across more than 30 international sites, and recruited 250 pati- ents per trial. The results of the trials are expected to be available by early December 2012 – following the completion of patient follow-up, data collection and the necessary statistical analyses. Starpharma also released its Appendix 4C – Quarterly Cashflow report for the period ended September 2012. The cash balance at 30 September 2012 was $37.6 million. Total operating and investing cash outflows for the quarter were $5.9 million; with net proceeds from the issue of shares totaling $0.8 million, resulting in a net decrease in cash of $5.1 million. The cash burn for the quarter is in line with budget.
http://www.starpharma.com
Stella Specialty Chemicals, a holding of Nanostart Asia Pacific, starts marketing of its products in Asia. The company has set up its manufacturing site in Singapore and all necessary licenses for the production of specialty chemicals have been granted by the authorities. The marketing strategy of the com- pany considers sales via distributors all over Asia as well as direct sales to OEMs in the region. A number of well known electronic component manufacturers have been served with trial shipments as potential Starpharma drug-dendrimer conjugate molecules. The primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93